

News Release

News Release

CONTACT: Andrew Bright
+ 1 (484) 530 3922
andrew.bright@oncure.com
www.oncure.com

ONCURE™ Announces an Agreement with North American Scientific Inc. for the Distribution of Prospera® Palladium-103 Prostate Brachytherapy Sources

Philadelphia (July 21, 2005) – ONCURE, a global leader in the minimally invasive management of prostate cancer announces a worldwide agreement to distribute North American Scientific's palladium-103 prostate brachytherapy source - Prospera. The agreement, which begins on September 9th, 2005 and runs for five years, allows ONCURE to offer its customers an uninterrupted supply of palladium-103 seeds. The seed will be available in the full range of presentation options demanded by brachytherapy programs today.

"ONCURE has entered into this partnership to ensure that we fully satisfy the needs of all prostate brachytherapy customers," said James McGlone, President and CEO of ONCURE. He added, "We've increased our long-term commitment to the brachytherapy community and look forward to the opportunity of providing an enhanced level of service; this agreement will allow us to do so."

Over one million palladium-103 seeds of this design have been sold since its introduction in 1999; it is supported by the peer reviewed, published dosimetry studies recommended by the American Association of Physicists in Medicine (AAPM). ONCURE will provide Prospera as a standard loose seed, in their unique and proven Strand, as well as in pre-loaded needles or Mick® cartridges. Added to its portfolio of leading iodine-125 products, RAPID Strand™, OncoSeed™ and EchoSeed™, the introduction of Prospera will offer increased convenience and flexibility for all prostate brachytherapy programs.

ONCURE was created through the merger of Amersham plc's (now GE Healthcare) brachytherapy business and Galil Medical Ltd's urology business. Galil is a subsidiary of Elron (ELRN). Headquartered in the United States, ONCURE operates as an independent business, with a major presence in the treatment of prostate cancer. ONCURE's International business is operated from its UK subsidiary. Please visit www.oncure.com for more information.

North American Scientific is a leader in radiation therapy products and services in the fight against cancer. Its innovative products provide physicians with a set of tools for the treatment of various types of cancers. They include radioisotope-based brachytherapy seeds, used primarily in the treatment of prostate cancer, marketed under the trade name Prospera®; Intensity Modulated Radiation Therapy (IMRT); and Image Guided Radiation Therapy (IGRT). Please visit www.nasmedical.com for more information.